UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Pursuant to~~Date ~~Section~~of 13Report ~~or 15~~(d)Date ofEarliest ~~the Securities~~Event ~~Exchange Act of 1934~~reported):

~~Date~~June of23, ~~Report~~2021 ~~(Date of earliest event reported)~~

June 15, 2021

PRA Health Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36732		46-3640387
(State or other jurisdiction of incorporation)		(Commission File Number)		(~~I.R.S.~~IRS Employer Identification No.)

4130 ParkLake Avenue

Suite 400

Raleigh, NC 27612

(919) 786-8200

(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Name of exchange on which registered		Trading symbol(s)
Common Stock, $0.01 par value		Nasdaq Global Select Market		PRAH

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.0702 ~~Submission~~Departure of ~~Matters~~Directors toor aCertain ~~Vote~~Officers; Appointment of ~~Security~~Certain ~~Holders~~Officers; Compensatory Arrangements of Certain Officers.

On June 1523, 2021, PRA Health Sciences, Inc., a Delaware corporation (“PRA”) ~~held~~amended athe ~~special~~employment ~~meeting~~agreements of ~~its~~Colin ~~stockholders~~Shannon (~~the~~President, ~~“Special~~Chief ~~Meeting”).~~Executive AsOfficer ~~of the~~and ~~close~~Chairman of ~~business~~the onBoard ~~April 26,~~of ~~2021~~Directors), ~~the~~Michael ~~record~~J. ~~date~~Bonello ~~for~~(Executive ~~the~~Vice ~~Special~~President ~~Meeting,~~and ~~64,795,400~~Chief ~~shares of~~Financial ~~common stock~~Officer), $0and Christopher L.01 ~~par~~Gaenzle (Chief ~~value~~Administrative ~~per~~Officer ~~share,~~and ofGeneral ~~PRA~~Counsel) (collectively the “~~PRA~~Named ~~Common~~Executive ~~Stock~~Officers”), ~~were~~in ~~outstanding~~connection ~~and~~with ~~entitled~~the ~~to vote. A~~Agreement ~~total~~and Plan of 52Merger,~~801,348~~ ~~shares~~by ofand among PRA, ICON ~~Common~~public ~~Stock~~limited ~~were~~company ~~voted in person or by proxy~~(“ICON”), ICON ~~representing~~US ~~approximately~~Holdings 81Inc.~~48%~~, ofand ~~the~~Indigo ~~shares~~Merger ~~entitled to be voted~~Sub, Inc., ~~which~~dated ~~constituted~~as aof ~~quorum~~February 24, to2021 ~~conduct business at~~ (the ~~Special~~“Merger ~~Meeting.~~Agreement” ~~The following are the final voting results on proposals considered~~ and ~~voted upon at~~ the ~~Special~~closing ~~Meeting,~~date ~~all~~ of ~~which~~the ~~are~~transactions ~~described~~contemplated by inthe ~~PRA’s~~Merger ~~Joint Proxy Statement/Prospectus~~Agreement, ~~which was filed with~~ the U“Closing”).~~S. Securities and Exchange Commission on April 28, 2021.~~

~~Each~~The employment agreements were amended to provide that: (i) the Closing constitutes a “change in control” for purposes of the Named Executive Officers’ employment agreements with PRA and any PRA equity compensation awards held by the ~~proposals~~Named ~~was~~Executive Officer ~~approved~~at the time of Closing, (ii) if ICON does not make an offer of continuing employment to the Named Executive Officers on or prior to the earlier of July 1, 2021 and the day that is ten (10) days prior to the Closing on the same terms and conditions as such Name Executive Officer’s employment with PRA (including but not limited to annual salary, cash bonus opportunities, long-term incentive opportunities, role/title at ICON and work location), then the Name Executive Officer shall have grounds to terminate his employment with PRA for “good reason” under his employment agreement and experience a “qualifying termination” for purposes of his outstanding PRA equity awards at Closing, and (iii) the “bonus” component of any cash severance payable to the Named Executive Officer pursuant to his employment agreement in respect of a termination of employment during the one-year period following the Closing shall be based on such Named Executive Officer’s 2021 target bonus. If the Closing does not occur for any reason or the Merger Agreement is terminated by its terms, then the ~~requisite~~amendments are terminated, and null and void. These amendments are permitted ~~vote~~by the terms of the Merger Agreement and are described on pages 167-168 “Interests of PRA’s ~~stockholders~~Directors and Executive Officers in the Merger—PRA Executive Employment Agreements” of the PRA/ICON F-4 filed on April 27, 2021.

~~Proposal~~The 1foregoing —summary Toof ~~adopt~~ the ~~Agreement~~employment agreement ~~and~~amendments ~~Plan~~does ofnot ~~Merger,~~purport ~~dated~~to asbe ofcomplete ~~February 24,~~and ~~2021,~~is byqualified ~~and~~in ~~among~~its ~~ICON~~entirety ~~plc~~by ~~(“ICON”),~~reference ~~PRA~~to ~~Health~~the ~~Sciences,~~Form ~~Inc.~~of ~~(“PRA”), ICON US~~Employment ~~Holdings~~Agreement ~~Inc.~~Amendment, a ~~wholly~~copy ~~owned subsidiary~~ of ~~ICON~~which ~~(“US~~is ~~HoldCo”),~~filed ~~and~~as ~~Indigo Merger Sub,~~Exhibit ~~Inc~~10.,1 ~~a wholly owned subsidiary of ICON and US HoldCo (such agreement, as it may be amended from time~~ to ~~time,~~this ~~the~~Current ~~“merger~~Report ~~agreement”~~on Form 8-K and ~~such~~is ~~proposal,~~incorporated ~~the “PRA~~herein ~~merger~~by ~~agreement proposal”)~~reference.

~~PRA’s~~Item ~~stockholders~~9.01 ~~approved~~Financial ~~the~~Statements ~~PRA~~and ~~merger agreement proposal~~Exhibits.

For		Against		Abstain
52,696,425		8,219		96,704

(d)

Exhibits.

Proposal 2 — To approve, on an advisory (non-binding) basis, the executive officer compensation that will or may be paid to PRA’s named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement (the “PRA compensation proposal”).

Exhibit No.	Description
10.1	Form of Employment Agreement Amendment.
104	The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

~~PRA’s stockholders approved the PRA compensation proposal.~~SIGNATURES

For		Against		Abstain
52,293,719		343,661		163,968

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Proposal 3 — To approve the adjournment of the PRA stockholder meeting to solicit additional proxies if there are not sufficient votes at the time of the PRA stockholder meeting to approve the PRA merger agreement proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to PRA stockholders (the “PRA adjournment proposal”).

	PRA Health Sciences, Inc.

Dated: June 25, 2021	By:	/s/ Christopher L. Gaenzle
		Name: Christopher L. Gaenzle
		Title: Executive Vice President, Chief Administrative Officer and General Counsel

PRA’s stockholders approved the PRA adjournment proposal, if necessary, but an adjournment was not necessary in light of adoption of the merger agreement.

For		Against		Abstain
48,962,035		3,721,701		117,612

Item 8.01 Other Events.

Based on the results of the Special Meeting, subject to the satisfaction or waiver of the remaining closing conditions under the merger agreement, the transactions contemplated by the merger agreement are expected to be consummated on July 1, 2021.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the potential transaction between ICON and PRA, including any statements regarding the expected timetable for completing the potential transaction, the ability to complete the potential transaction, the expected benefits of the potential transaction (including anticipated synergies, projected financial information and future opportunities) and any other statements regarding ICON’s and PRA’s future expectations, beliefs, plans, objectives, results of operations, financial condition and cash flows, or future events or performance. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar expressions. All such forward-looking statements are based on current expectations of ICON’s and PRA’s management and therefore involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking statements include uncertainties as to the timing to consummate the potential transaction; the risk that a condition to closing the potential transaction may not be satisfied; litigation relating to the potential transaction that has been or could be instituted against ICON, PRA or their respective directors; the effects of disruption to ICON’s or PRA’s respective businesses; restrictions during the pendency of the potential transaction that may impact ICON’s or PRA’s ability to pursue certain business opportunities or strategic transactions; the effect of this communication on ICON’s or PRA’s stock prices; transaction costs; ICON’s ability to achieve the benefits from the proposed transaction; ICON’s ability to effectively integrate acquired operations into its own operations; the ability of ICON or PRA to retain and hire key personnel; unknown liabilities; and the diversion of management time on transaction-related issues. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include the effects of industry, market, economic, political or regulatory conditions outside of ICON’s or PRA’s control (including public health crises, such as pandemics and epidemics); risks regarding PRA’s ability to maintain large customer contracts or enter into new contracts; PRA’s ability to attract suitable investigators and patients for its clinical trials; PRA’s ability to keep pace with rapid technological change; PRA’s potential liability if a patient is harmed; and the factors set forth under the heading “Risk Factors” of ICON’s Annual Report on Form 20-F and PRA’s Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and in subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks, as well as other risks associated with the potential transaction, are more fully discussed in the joint proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Other unpredictable or unknown factors not discussed in this communication could also have material adverse effects on forward-looking statements. Neither ICON nor PRA assumes any obligation to update any forward-looking statements, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRA Health Sciences, Inc.
Dated: June 16, 2021	By:	/s/ Christopher L. Gaenzle
		Name: Christopher L. Gaenzle
		Title: Executive Vice President, Chief Administrative Officer and General Counsel

Filing Compare · PRA Health Sciences, Inc.